Overview

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Posi

Status:
Completed

Trial end date:
2017-10-11

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or recommended dose for phase 2 study (RDP2) of alobresib as a monotherapy in participants with advanced solid tumors and lymphomas, and in combination with exemestane or fulvestrant in participants with advanced estrogen receptor positive breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Estradiol
Estrogens
Exemestane
Fulvestrant